Clinical factors associated with response to ruxolitinib in patients with myelofibrosis
A dysregulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is characteristic of myelofibrosis (MF). Ruxolitinib, a potent...
"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You are sure to find a response to your burning questions about MPN here!"